<DOC>
	<DOCNO>NCT01038999</DOCNO>
	<brief_summary>The main goal confirm , among HIV1-infected patient , data vitro study show antiretroviral therapy induce accelerate age mechanisms genetic laminopathies `` physiological `` aging , synthesis persistence farnesylated prelamin A . The secondary goal measure impact HIV infection antiretroviral therapy marker cell age ( proteasome , mitochondrion , telomere ) . The perspective fix antiretroviral therapy side effect use drug combination use week Marseille treat child suffer progeria</brief_summary>
	<brief_title>Accelerated Aging , HIV Infection , Antiretroviral Therapies</brief_title>
	<detailed_description>Protease inhibitor block viral protease , well various cell enzyme : ZMPSTE24 clip prelamin A mature lamin A ; least one Golgi proteases involve release SREBP , control transcription lipid metabolism regulate gene ; mitochondrial protease involve importation maturation nuclear genome encode protein ; proteasome regulate transcription several gene NF-B ; P450 cytochrome . Nucleosides inhibitor viral reverse transcriptase exhibit nuclear mitochondrial DNA toxicity , disrupt lipid protein glycosylation inhibit telomerase . Therefore antiretroviral therapy target several pathway involve accelerated normal age . Their combined effect add viral infection direct symptom cell abnormality induce viral protein . Our multicentric ( 3 CISIH Marseille , Nice Montpellier ) 3 year- long study analyse 50 HIV1-infected naive patient ( A group ) , apparied 50 age- sex-matched seronegative control subject ( recruit CIC-UPCET Marseille ) 100 HIV1-infected patient first line antiretroviral therapy least 12 month ( B group ) . Patients group A B recruit 3 clinical unit . The HIV1- infected patient evaluate four time , baseline , every 12 month 3 year . In case initiation change antiretroviral therapy , patient evaluate . Control subject evaluate baseline . Peripheral blood biological test follow [ Laboratory designation ] : i/ viral load measurement , PBMC isolation , DNA extraction , proviral DNA measurement , cell DNA storage [ Virology , Timone CHU , Marseille ] ; ii/ assay CD4 , CD8 , glycemia , insulinemia , HOMA , total- , LDL- HDL-cholesterol , triglycerides [ Biochemistry labs 3 CHU ] ; iii/ antiretroviral drug assay ( mass spectrometry ) [ Pharmacokinetics , Timone CHU , Marseille ] ; iv/ detection ( western blotting , immunocytochemistry combine image analysis nuclear abnormality ) PBMC nuclear , cytosolic mitochondrial target antiretroviral drug : A B lamins , NF-B + I-B proteasome activity assay , CD36 ( glycosylation ) , mitochondrial Hsp70 , ROS mitochondrial production , mitochondrial inner membrane potential , cytochrome C oxidase subunits 2 4 [ Cell Biology , Timone CHU , Marseille ] ; v/ genotyping antiretroviral target : lamin A ( ZMPSTE24 ) B ( Rce1 ) processing protease , Golgi SREBP-releasing protease ( MBTPS1 S2 ) , mitochondrial deoxynucleoside transporter ( SLC25A4 A6 ) , mitochondrial protease ( MPPA , paraplegin ) involve process nuclear encoded protein mitochondrial import ; quantitative PCR measurement telomere length [ Molecular Genetics , Timone CHU , Marseille ] . Marseille 's CIC-UPCET collaborate protocol design , recruit control subject responsible statistical treatment data .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Age â‰¥ 18 year &lt; 65 year Able give write consent Covered French Social Security Non infect HIV2 A group HIV1infected naive patient B group infect patient first line antiretroviral therapy least 12 month C group HIV seronegative Confirmed fast test screen HIV day one study Age &lt; 18 year &gt; 65 year Not Able give write consent Not Covered French Social Security Infected HIV2 treat statin biphosphonat amino concomitant treatment : diabetic testosteron</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Complementary Therapies</keyword>
</DOC>